Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SIRS-Lab GmbH has entered into a collaboration with the US-based bio-medical company Biosite Incorporated for the evaluation and potential commercialization of sepsis markers.
Subscribe to our email newsletter
Under the collaboration, SIRS-Lab will provide access to selected biomarkers for sepsis. Biosite will then make antibodies to those selected targets using the company’s proprietary antibody development process, which combines immunization of mice and phage display to generate highly diverse libraries of Omniclonal antibodies with high affinity and low cross-reactivity.
The antibodies will be used to generate assays for the measurement of the selected biomarker targets in blood samples. Validated biomarkers will then be assessed for commercialization potential, with high-value markers added to Biosite’s product development process.
“We are delighted to work with Biosite to evaluate the potential value of our sepsis biomarkers for clinical diagnostic applications,” said Dr Stefan Russwurm, SIRS-Lab’s CEO. “This agreement combines the strengths of both companies: Biosite’s proven antibody development and commercialization process for diagnostic products with our expertise in molecular medicine concerning inflammatory diseases.”
The financial terms of the agreement were not disclosed.